Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Frankfurt - Delayed Quote EUR

Abeona Therapeutics Inc. (PCJ.F)

Compare

4.8400

-0.0800

(-1.63%)

At close: February 28 at 8:07:15 AM GMT+1

Abeona Therapeutics Inc.'s (NASDAQ:ABEO) Shift From Loss To Profit

We feel now is a pretty good time to analyse Abeona Therapeutics Inc.'s ( NASDAQ:ABEO ) business as it appears the...

Simply Wall St. 21 days ago

ABEO
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CLEVELAND, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On January 31, 2024, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to eight individuals hired by Abeona, which equity awards relate to, in the

GlobeNewswire 25 days ago

ABEO
Owning 43% shares,institutional owners seem interested in Abeona Therapeutics Inc. (NASDAQ:ABEO),

Key Insights Significantly high institutional ownership implies Abeona Therapeutics' stock price is sensitive to their...

Simply Wall St. 2 months ago

ABEO
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025

ATLANTIC CITY, NJ / ACCESSWIRE / November 27, 2024 /DealFlow Events is pleased to announce the initial lineup of companies participating in The Microcap Conference, set for January 28-30 in Atlantic City, NJ. Now in its second year, the event is a ...

ACCESS Newswire 3 months ago

ASNS

BETR

BETRW
ABEO: FDA Accepts BLA Re-Submission for Pz-cel; PDUFA Date of April 29, 2025; Raising Valuation to $9.50…

By David Bautz, PhD NASDAQ:ABEO READ THE FULL ABEO RESEARCH REPORT Business Update BLA Resubmission Accepted; PDUFA Date of April 29, 2025 On November 12, 2024, Abeona Therapeutics, Inc. (NASDAQ:ABEO) announced that the U.S. FDA has accepted the Biologics License Application (BLA) for prademagene zamikeracel (pz-cel) and set a PDUFA target action date of April 29, 2025. The resubmission of the

Zacks Small Cap Research 3 months ago

ABEO
Abeona Therapeutics Inc (ABEO) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...

Abeona Therapeutics Inc (ABEO) navigates regulatory hurdles and competition while preparing for the commercial launch of its innovative therapy.

GuruFocus.com 3 months ago

ABEO
Abeona Therapeutics: Q3 Earnings Snapshot

CLEVELAND (AP) — Abeona Therapeutics Inc. ABEO) on Thursday reported a loss of $20.3 million in its third quarter. On a per-share basis, the Cleveland-based company said it had a loss of 42 cents.

Associated Press Finance 3 months ago

ABEO
Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

FDA accepts BLA resubmission of pz-cel in recessive dystrophic epidermolysis bullosa and sets PDUFA target action date of April 29, 2025 Company makes significant progress toward potential commercialization of pz-cel in 2025; Builds momentum with payor discussions and target treatment centers CLEVELAND, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the third quarter ended September 30, 2024, and recent corporate updates. “With the

GlobeNewswire 3 months ago

ABEO
Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

FDA assigns PDUFA target action date of April 29, 2025CLEVELAND, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Abeona’s resubmission of its Biologics License Application (BLA) for prademagene zamikeracel (pz-cel), its investigational autologous cell-based gene therapy, as a potential new treatment for recessive dystrophic epidermolysis bullosa (RDEB). The FDA has assigned a Prescr

GlobeNewswire 3 months ago

ABEO
Abeona Therapeutics® Announces Participation in November Investor Conferences

CLEVELAND, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in November 2024: Truist Securities BioPharma Symposium: Investor meetings on Thursday, November 7, 2024.Stifel 2024 Healthcare Conference: Fireside chat on Monday, November 18, 2024 at 4:10 p.m. ET and investor meetings. A live webcast of the fireside chat can be accessed on the Investors section of the Abeona

GlobeNewswire 3 months ago

ABEO
Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration

CLEVELAND, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the Company has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA or Agency) for prademagene zamikeracel (pz-cel), its investigational autologous cell-based gene therapy, as a potential new treatment for patients with recessive dystrophic epidermolysis bullosa (RDEB). “We have worked closely with the FDA in preparing for the pz-cel BLA resubmis

GlobeNewswire 3 months ago

ABEO
Abeona Therapeutics Inc (ABEO) Q2 2024 Earnings Call Highlights: Strong Financial Performance ...

Abeona Therapeutics Inc (ABEO) reports a net income boost and strategic progress, despite challenges in BLA resubmission timeline.

GuruFocus.com 4 months ago

ABEO
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

CLEVELAND, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in September 2024: Wells Fargo Healthcare Conference: Investor meetings on Thursday, September 5, 2024.H.C. Wainwright Annual Global Investment Conference: Company presentation on Tuesday, September 10, 2024 at 1:30 p.m. ET and investor meetings.Cantor Global Healthcare Conference: Fireside chat on Thursday, Se

GlobeNewswire 5 months ago

ABEO
ABEO: Type A Meeting with FDA Concluded; BLA Submission on Track for 2H24…

By David Bautz, PhD NASDAQ:ABEO READ THE FULL ABEO RESEARCH REPORT Business Update Type A Meeting with FDA Complete; BLA Resubmission in 2H24 Abeona Therapeutics, Inc. (NASDAQ:ABEO) is currently working on the resubmission of the Biologics License Application (BLA) for pz-cel (prademagene zamikeracel) for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Recently, Abeona

Zacks Small Cap Research 6 months ago

ABEO
Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors

CLEVELAND, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Bernhardt G. Zeiher, MD, FCCP, FACP, and Eric Crombez, MD as new independent members to its Board of Directors. Dr. Zeiher brings more than 20 years of drug development experience where, in various roles, he oversaw the approval of 15 new treatments that addressed unmet needs in serious diseases with few to no treatment options. Dr. Crombez currently serves as Chief Medical Off

GlobeNewswire 6 months ago

ABEO
Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-cel

CMS grants ICD-10-PCS product-specific procedure code and favorable DRG assignment for pz-cel, supporting efficient hospital billing, reimbursement and patient accessCLEVELAND, Ohio, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the Centers for Medicare and Medicaid Services (CMS) has granted a product-specific procedure code ICD-10-PCS (International Classification of Diseases, 10th Revision, Procedure Coding System) for prademagene zamikeracel (

GlobeNewswire 6 months ago

ABEO
Abeona Therapeutics: Q2 Earnings Snapshot

CLEVELAND (AP) — Abeona Therapeutics Inc. ABEO) on Monday reported second-quarter net income of $7.4 million, after reporting a loss in the same period a year earlier. On a per-share basis, the Cleveland-based company said it had net loss of 26 cents.

Associated Press Finance 6 months ago

ABEO
Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission

Significant progress addressing CMC items noted in CRL BLA resubmission remains on track for 2H 2024 CLEVELAND, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the second quarter of 2024 and recent corporate progress. “Having completed data generation for nearly all of the Chemistry Manufacturing and Controls deliverables outlined in the Complete Response Letter that we received in April 2024, we are on track to resubmit our Biologic

GlobeNewswire 6 months ago

ABEO
Institutional investors own a significant stake of 39% in Abeona Therapeutics Inc. (NASDAQ:ABEO)

Key Insights Given the large stake in the stock by institutions, Abeona Therapeutics' stock price might be vulnerable...

Simply Wall St. 7 months ago

ABEO
Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications

CLEVELAND and LONDON, July 11, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a cell and gene therapy company with proprietary adeno-associated virus (AAV)-based capsids, and Beacon Therapeutics, an ophthalmic gene therapy company and Syncona portfolio company, today announced an agreement by which Beacon will evaluate Abeona's patented AAV204 capsid for the development and commercialization of potential gene therapies for select ophthalmology indications. “This agreement with

GlobeNewswire 7 months ago

ABEO

Performance Overview

Return	PCJ.F	S&P 500
YTD	-7.81%	+1.24%
1-Year	-26.83%	+17.45%
3-Year	-35.47%	+36.14%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Abeona Therapeutics Inc. (PCJ.F)

Abeona Therapeutics Inc.'s (NASDAQ:ABEO) Shift From Loss To Profit

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Owning 43% shares,institutional owners seem interested in Abeona Therapeutics Inc. (NASDAQ:ABEO),

DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025

ABEO: FDA Accepts BLA Re-Submission for Pz-cel; PDUFA Date of April 29, 2025; Raising Valuation to $9.50…

Abeona Therapeutics Inc (ABEO) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...

Abeona Therapeutics: Q3 Earnings Snapshot

Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

Abeona Therapeutics® Announces Participation in November Investor Conferences

Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration

Abeona Therapeutics Inc (ABEO) Q2 2024 Earnings Call Highlights: Strong Financial Performance ...

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

ABEO: Type A Meeting with FDA Concluded; BLA Submission on Track for 2H24…

Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors

Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-cel

Abeona Therapeutics: Q2 Earnings Snapshot

Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission

Institutional investors own a significant stake of 39% in Abeona Therapeutics Inc. (NASDAQ:ABEO)

Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications

Performance Overview